Aratana Therapeutics Inc. (PETX) Stock Price & Overview

NASDAQ:PETX

Current stock price

4.92
-0.01 (-0.2%)
At close:
5.02
+0.1 (+2.03%)
After Hours:

The current stock price of PETX is 4.92 null. Today PETX is down by -0.2%. In the past month the price increased by 0.61%. In the past year, price increased by 9.82%.

PETX Key Statistics

52-Week Range3.3 - 7.16
Current PETX stock price positioned within its 52-week range.
1-Month Range4.8 - 5.3
Current PETX stock price positioned within its 1-month range.
Market Cap
240.927M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.27
Dividend Yield
N/A

PETX Stock Performance

Today
-0.2%
1 Week
-1.40%
1 Month
+0.61%
3 Months
+40.57%
Longer-term
6 Months +11.31%
1 Year +9.82%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

PETX Stock Chart

Aratana Therapeutics Inc. / PETX Daily stock chart

PETX Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to PETX. When comparing the yearly performance of all stocks, PETX is one of the better performing stocks in the market, outperforming 93.61% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating
PETX Full Technical Analysis Report

PETX Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to PETX. PETX is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
PETX Full Fundamental Analysis Report

PETX Earnings

Next Earnings DateN/A
Last Earnings DateN/A
PETX Earnings History

PETX Forecast & Estimates


Analysts
Analysts60
Price TargetN/A
EPS Next Y9.38%
Revenue Next YearN/A
PETX Forecast & Estimates

PETX Financial Highlights

Over the last trailing twelve months PETX reported a non-GAAP Earnings per Share(EPS) of -0.27. The EPS increased by 68.24% compared to the year before.


Income Statements
Revenue(TTM)38.73M
Net Income(TTM)-12.96M
Industry RankSector Rank
PM (TTM) -33.47%
ROA -12.38%
ROE -13.47%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%26.32%
Sales Q2Q%82.04%
EPS 1Y (TTM)68.24%
Revenue 1Y (TTM)49.99%
PETX financials

PETX Ownership

Ownership
Inst Owners65%
Shares48.97M
Float32.79M
Ins Owners9.4%
Short Float %N/A
Short RatioN/A
PETX Ownership

About PETX

Company Profile

Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative pain. It operates in the United States and Europe. Aratana Therapeutics Inc. is headquartered in Kansas City, Kansas.

Company Info

Aratana Therapeutics Inc.

11400 TOMAHAWK CREEK PARKWAY SUITE 340

LEAWOOD KS 66211

CEO: Craig A. Tooman

Phone: 913-353-1000

Aratana Therapeutics Inc. / PETX FAQ

What does Aratana Therapeutics Inc. do?

Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative pain. It operates in the United States and Europe. Aratana Therapeutics Inc. is headquartered in Kansas City, Kansas.


What is the stock price of Aratana Therapeutics Inc. today?

The current stock price of PETX is 4.92 null. The price decreased by -0.2% in the last trading session.


Does Aratana Therapeutics Inc. pay dividends?

PETX does not pay a dividend.


What is the ChartMill rating of Aratana Therapeutics Inc. stock?

PETX has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 5 out of 10.